Literature DB >> 30603117

Daily breathing inconsistency in pancreas SBRT: a 4DCT study.

Vikren Sarkar1, Shane Lloyd1, Adam Paxton1, Long Huang1, Fan-Chi Su1, Randa Tao1, Jonathan Tward1, Hui Zhao1, Bill Salter1.   

Abstract

BACKGROUND: Stereotactic body radiation therapy (SBRT) treatments of pancreatic cancer typically employ relatively small margins. This study characterizes the motion of high visibility structures in close proximity to the pancreas to determine how much the motion envelope of such a structure changes due to respiratory variation between fractions.
METHODS: Fanbeam, four-dimensional computed tomography (4DCT) studies acquired initially for planning and again prior to each treatment for 6 patients were used to fully characterize the change in motion of high-contrast structures in close proximity to the pancreas.
RESULTS: Three of the six patients investigated had structures that showed a change in motion over the course of treatment that would not have been covered when using the typical 3 mm planning target volume (PTV) margins. For most of these large changes in motion envelope, a 4 mm uniform PTV margin would have allowed for coverage of the tumor.
CONCLUSIONS: Half of the patients showed a change in motion envelope greater than would be covered by the commonly used PTV margins in pancreas SBRT. This shows that the impact of small margins must be very carefully considered during the planning process.

Entities:  

Keywords:  Pancreas stereotactic body radiation therapy (pancreas SBRT); planning target volume margins (PTV margins); respiratory motion

Year:  2018        PMID: 30603117      PMCID: PMC6286933          DOI: 10.21037/jgo.2018.09.08

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  12 in total

1.  Use of respiratory-correlated four-dimensional computed tomography to determine acceptable treatment margins for locally advanced pancreatic adenocarcinoma.

Authors:  Seth D Goldstein; Eric C Ford; Mario Duhon; Todd McNutt; John Wong; Joseph M Herman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-14       Impact factor: 7.038

2.  Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.

Authors:  Qing Zhao; Asif Rashid; Yun Gong; Matthew H Katz; Jeffrey E Lee; Robert Wolf; Aparna Balachandran; Gauri R Varadhachary; Peter W Pisters; Hua Wang; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Ann Diagn Pathol       Date:  2011-11-03       Impact factor: 2.090

3.  Changes in the respiratory pattern during radiotherapy for cancer in the lung.

Authors:  Geoffrey Hugo; Carlos Vargas; Jian Liang; Larry Kestin; John W Wong; Di Yan
Journal:  Radiother Oncol       Date:  2006-03-27       Impact factor: 6.280

4.  Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation.

Authors:  Sunil Krishnan; Awalpreet S Chadha; Yelin Suh; Hsiang-Chun Chen; Arvind Rao; Prajnan Das; Bruce D Minsky; Usama Mahmood; Marc E Delclos; Gabriel O Sawakuchi; Sam Beddar; Matthew H Katz; Jason B Fleming; Milind M Javle; Gauri R Varadhachary; Robert A Wolff; Christopher H Crane
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-12-11       Impact factor: 7.038

5.  Pancreatic tumor motion on a single planning 4D-CT does not correlate with intrafraction tumor motion during treatment.

Authors:  A Yuriko Minn; Devin Schellenberg; Peter Maxim; Yelin Suh; Stephen McKenna; Brett Cox; Sonja Dieterich; Lei Xing; Edward Graves; Karyn A Goodman; Daniel Chang; Albert C Koong
Journal:  Am J Clin Oncol       Date:  2009-08       Impact factor: 2.339

6.  Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy.

Authors:  Yvette Seppenwoolde; Hiroki Shirato; Kei Kitamura; Shinichi Shimizu; Marcel van Herk; Joos V Lebesque; Kazuo Miyasaka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-15       Impact factor: 7.038

7.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.

Authors:  Douglas B Evans; Gauri R Varadhachary; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Huamin Wang; Karen R Cleary; Gregg A Staerkel; Chusilp Charnsangavej; Elizabeth A Lano; Linus Ho; Renato Lenzi; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

8.  Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Authors:  Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

9.  The role of surgical clips in the evaluation of interfractional uncertainty for treatment of hepatobiliary and pancreatic cancer with postoperative radiotherapy.

Authors:  Jin Suk Bae; Dong Hyun Kim; Won Taek Kim; Yong Ho Kim; Dahl Park; Yong Kan Ki
Journal:  Radiat Oncol J       Date:  2017-03-10

10.  Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer.

Authors:  Daniel L P Holyoake; Maxwell Robinson; Derek Grose; David McIntosh; David Sebag-Montefiore; Ganesh Radhakrishna; Neel Patel; Mike Partridge; Somnath Mukherjee; Maria A Hawkins
Journal:  Radiother Oncol       Date:  2016-08-09       Impact factor: 6.280

View more
  1 in total

1.  Study on Motion Management of Pancreatic Cancer Treated by CyberKnife.

Authors:  Shenghua Jing; Changchen Jiang; Xiaoqin Ji; Xiangnan Qiu; Jing Li; Xiangdong Sun; Xixu Zhu
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.